DK3652176T3 - Substituerede xanthinderivater - Google Patents

Substituerede xanthinderivater Download PDF

Info

Publication number
DK3652176T3
DK3652176T3 DK18735588.8T DK18735588T DK3652176T3 DK 3652176 T3 DK3652176 T3 DK 3652176T3 DK 18735588 T DK18735588 T DK 18735588T DK 3652176 T3 DK3652176 T3 DK 3652176T3
Authority
DK
Denmark
Prior art keywords
substituted
xanthin derivatives
xanthin
derivatives
substituted xanthin
Prior art date
Application number
DK18735588.8T
Other languages
Danish (da)
English (en)
Inventor
Kai Gerlach
Christian Eickmeier
Achim Sauer
Stefan Just
Bertrand L Chenard
Original Assignee
Boehringer Ingelheim Int
Hydra Biosciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int, Hydra Biosciences Llc filed Critical Boehringer Ingelheim Int
Application granted granted Critical
Publication of DK3652176T3 publication Critical patent/DK3652176T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK18735588.8T 2017-07-11 2018-07-06 Substituerede xanthinderivater DK3652176T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17180721 2017-07-11
PCT/EP2018/068366 WO2019011802A1 (en) 2017-07-11 2018-07-06 NEW SUBSTITUTED XANTHINE DERIVATIVES

Publications (1)

Publication Number Publication Date
DK3652176T3 true DK3652176T3 (da) 2022-01-17

Family

ID=59325162

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18735588.8T DK3652176T3 (da) 2017-07-11 2018-07-06 Substituerede xanthinderivater

Country Status (32)

Country Link
US (1) US10329292B2 (enExample)
EP (1) EP3652176B1 (enExample)
JP (1) JP7114702B2 (enExample)
KR (1) KR102714554B1 (enExample)
CN (1) CN110997675B (enExample)
AR (1) AR112448A1 (enExample)
AU (1) AU2018299824B2 (enExample)
CA (1) CA3066922A1 (enExample)
CL (1) CL2020000056A1 (enExample)
CO (1) CO2019015102A2 (enExample)
CY (1) CY1125014T1 (enExample)
DK (1) DK3652176T3 (enExample)
EA (1) EA039526B1 (enExample)
ES (1) ES2903268T3 (enExample)
HR (1) HRP20220029T1 (enExample)
HU (1) HUE057600T2 (enExample)
IL (1) IL271799B (enExample)
LT (1) LT3652176T (enExample)
MX (1) MX394089B (enExample)
MY (1) MY200797A (enExample)
PE (1) PE20200861A1 (enExample)
PH (1) PH12020500079A1 (enExample)
PL (1) PL3652176T3 (enExample)
PT (1) PT3652176T (enExample)
RS (1) RS62826B1 (enExample)
SA (1) SA519410851B1 (enExample)
SG (1) SG11201912168TA (enExample)
SI (1) SI3652176T1 (enExample)
SM (1) SMT202200013T1 (enExample)
TW (1) TWI801398B (enExample)
UA (1) UA124793C2 (enExample)
WO (1) WO2019011802A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3761989A4 (en) * 2018-03-05 2021-11-24 Goldfinch Bio, Inc. IMIDAZODIAZEPINEDIONE AND METHOD OF USE THEREOF
AU2019396499B2 (en) * 2018-12-12 2024-10-10 Boehringer Ingelheim International Gmbh Substituted xanthine derivatives
EP3894409B1 (en) * 2018-12-12 2023-08-23 Boehringer Ingelheim International GmbH Substituted xanthine derivatives
EP4037680A4 (en) * 2019-10-04 2023-10-04 Goldfinch Bio, Inc. BIOMARKER-BASED TREATMENT OF FOCAL SEGMENTAL GLOMERULOSSCLEROSIS AND DIABETIC KIDNEY DISEASE
WO2024153028A1 (zh) * 2023-01-20 2024-07-25 深圳晶蛋生物医药科技有限公司 大环类化合物、其药物组合物及其应用
CN118459461A (zh) * 2023-02-08 2024-08-09 中国科学院上海药物研究所 黄嘌呤类化合物及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU230384B1 (hu) * 2001-02-24 2016-03-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xantinszármazékok, előállításuk és alkalmazásuk gyógyszerként
US6869947B2 (en) * 2001-07-03 2005-03-22 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
ATE496894T1 (de) * 2006-07-14 2011-02-15 Pfizer Prod Inc Tartratsalz von (7s)-7-ä(5-fluor-2-
DK2970303T6 (en) * 2013-03-15 2018-10-08 Hydra Biosciences Inc SUBSTITUTED XANTHINES AND PROCEDURES FOR USING IT
TWI676626B (zh) * 2014-04-23 2019-11-11 美商美國禮來大藥廠 抑制瞬時受體電位a1離子通道
EP3180340B1 (en) * 2014-08-11 2018-10-10 Hydra Biosciences, Inc. Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives
JP6667092B2 (ja) * 2014-08-11 2020-03-18 ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーHydra Biosciences, LLC ピロロ[3,2−d]ピリミジン−2,4(3H,5H)−ジオン誘導体
WO2016041845A1 (en) 2014-09-17 2016-03-24 Boehringer Ingelheim International Gmbh Tetrahydroisoquinoline derivatives and pharmaceutical compositions useful for the treatment of obesity and diabetes

Also Published As

Publication number Publication date
KR20200030048A (ko) 2020-03-19
EP3652176A1 (en) 2020-05-20
MY200797A (en) 2024-01-16
CN110997675A (zh) 2020-04-10
NZ759728A (en) 2024-11-29
EP3652176B1 (en) 2021-12-15
JP7114702B2 (ja) 2022-08-08
AR112448A1 (es) 2019-10-30
CO2019015102A2 (es) 2020-05-15
BR112019025611A2 (pt) 2020-06-16
PE20200861A1 (es) 2020-08-25
CA3066922A1 (en) 2019-01-17
LT3652176T (lt) 2022-02-25
SMT202200013T1 (it) 2022-03-21
PL3652176T3 (pl) 2022-04-04
SI3652176T1 (sl) 2022-04-29
PH12020500079A1 (en) 2020-10-05
WO2019011802A1 (en) 2019-01-17
EA202090270A1 (ru) 2020-04-24
JP2020526591A (ja) 2020-08-31
IL271799B (en) 2022-08-01
ES2903268T3 (es) 2022-03-31
EA039526B1 (ru) 2022-02-07
AU2018299824B2 (en) 2022-06-16
MX394089B (es) 2025-03-24
TWI801398B (zh) 2023-05-11
US20190016722A1 (en) 2019-01-17
UA124793C2 (uk) 2021-11-17
SG11201912168TA (en) 2020-01-30
CY1125014T1 (el) 2023-03-24
CN110997675B (zh) 2022-06-07
HUE057600T2 (hu) 2022-05-28
IL271799A (en) 2020-02-27
TW201908318A (zh) 2019-03-01
CL2020000056A1 (es) 2020-06-12
RS62826B1 (sr) 2022-02-28
PT3652176T (pt) 2022-01-13
AU2018299824A1 (en) 2019-12-19
US10329292B2 (en) 2019-06-25
SA519410851B1 (ar) 2023-02-26
HRP20220029T1 (hr) 2022-04-15
KR102714554B1 (ko) 2024-10-10
MX2020000402A (es) 2020-08-17

Similar Documents

Publication Publication Date Title
DK3319956T3 (da) Substituerede oxopyridinderivater
DK3687999T3 (da) Rapamycinderivater
DK3642202T3 (da) Dihydro-pyrrolo-pyridin-derivater
EP3496717A4 (en) 4-substituted aminoisoquinoline derivatives
LT3830085T (lt) Deuterinti lanifibranoro dariniai
IL265166B (en) Anti-influenza virus pyrimidine derivatives
LT3204359T (lt) Tetrahidroizochinolino dariniai
LT3402792T (lt) Chinolin-2-ono dariniai
EP3546462A4 (en) NEW OXOISOQUINOLINE DERIVATIVE
DK3768669T3 (da) Piperazinazaspiroderivater
LT3457851T (lt) Sobetiromo dariniai
HUE048321T2 (hu) Karabazol származékok
LT3371168T (lt) Indolin-2-ono dariniai
EP3564216A4 (en) PYRIMIDINE DERIVATIVE
DK3652176T3 (da) Substituerede xanthinderivater
DK3231803T3 (da) Dihydroindolizinonderivat
DK3823970T3 (da) Yderligere substituerede triazoloquinoxalinderivater
EP3309163A4 (en) SUBSTITUTED DIHYDROPYRROLO PYRAZOL DERIVATIVE
DK3131898T3 (da) Fluoroalkylfluorenderivativer
DK3823971T3 (da) Substituerede triazol-quinoxalin-derivater
DK3679038T3 (da) Substituerede imidazoquinoliner
DK3796975T3 (da) Sulfonylaminobenzamidderivater
EP3444345C0 (en) MICRO-143 RNA DERIVATIVE
DK3372589T3 (da) Pyrimidinderivat
DK3645513T3 (da) Benzazepinderivater